Published in Nature on November 25, 2015
Lessons learned from studying syndromic autism spectrum disorders. Nat Neurosci (2016) 1.04
Clinical and biological progress over 50 years in Rett syndrome. Nat Rev Neurol (2016) 0.95
Restoration of Mecp2 expression in GABAergic neurons is sufficient to rescue multiple disease features in a mouse model of Rett syndrome. Elife (2016) 0.87
Gene-targeting pharmaceuticals for single-gene disorders. Hum Mol Genet (2015) 0.84
Developmental Dynamics of Rett Syndrome. Neural Plast (2016) 0.82
SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci (2017) 0.81
Genetic Approaches to Understanding Psychiatric Disease. Neurotherapeutics (2017) 0.80
The Role of Epigenetic Mechanisms in the Regulation of Gene Expression in the Nervous System. J Neurosci (2016) 0.78
Influenza A induces dysfunctional immunity and death in MeCP2-overexpressing mice. JCI Insight (2017) 0.75
Neurogenetics: Restoring levels. Nat Rev Neurosci (2015) 0.75
Epigenetic Effect of Environmental Factors on Autism Spectrum Disorders. Int J Environ Res Public Health (2016) 0.75
MiR-130a regulates neurite outgrowth and dendritic spine density by targeting MeCP2. Protein Cell (2016) 0.75
Distinct Defects in Spine Formation or Pruning in Two Gene Duplication Mouse Models of Autism. Neurosci Bull (2017) 0.75
FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype. Hum Gene Ther (2016) 0.75
Loss-of-function mutation in Mirta22/Emc10 rescues specific schizophrenia-related phenotypes in a mouse model of the 22q11.2 deletion. Proc Natl Acad Sci U S A (2017) 0.75
Differential expression analysis for sequence count data. Genome Biol (2010) 64.56
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol (2013) 32.42
HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics (2014) 23.22
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet (1998) 13.27
MeCP2, a key contributor to neurological disease, activates and represses transcription. Science (2008) 10.11
Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell (1992) 8.10
Reversal of neurological defects in a mouse model of Rett syndrome. Science (2007) 7.09
Correction of fragile X syndrome in mice. Neuron (2007) 6.51
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med (2008) 5.15
Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature (2010) 5.11
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol (2010) 4.86
CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell (2012) 4.81
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature (2006) 4.80
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet (2004) 4.45
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature (2011) 4.04
Characterization of Potocki-Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. Am J Hum Genet (2007) 3.26
Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature (2002) 3.05
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med (2011) 2.56
The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Nat Genet (1992) 2.08
Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum Mol Genet (2009) 2.00
SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature (2013) 1.86
The MECP2 duplication syndrome. Am J Med Genet A (2010) 1.68
Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet (2008) 1.34
Anxiety-related behaviors in the elevated zero-maze are affected by genetic factors and retinal degeneration. Behav Neurosci (2001) 1.28
Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome. Nat Genet (2012) 1.26
Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. Nat Med (2013) 1.20
XLMR syndrome characterized by multiple respiratory infections, hypertelorism, severe CNS deterioration and early death localizes to distal Xq28. Am J Med Genet (1999) 1.15
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med (2012) 1.14
MeCP2: only 100% will do. Nat Neurosci (2012) 1.05